Is Quifenadine an antihistamine of the first generation? Do we know everything…

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Quifenadine was developed in the 1970s in the laboratory of M.D. Mashkovsky and is one of the first examples of the creation of a new class of non-sedative antihistamine with polyfunctional action that combines high selective activity to block histamine receptor type 1 and the ability to block serotonin action and increase tissue histaminase activity.

There is a large experience in the use of quifenadine (based on scientific clinical studies and real clinical practice). The total number of patients involved in the trials reached approximately 2000. The studies evaluated the quifenadipharmacokinetics, pharmacodynamics, clinical efficacy, and safety of the grug. The results of a clinical study of quiphenadine showed high therapeutic efficacy in a variety of allergic diseases (allergic rhinitis, atopy and atom-atopic dermatitis, chronic urticaria).

Quiphenadine meets the current requirements for antihistamines, however, the question remains open, which generation of drugs can be classified as quinuclidine, taking into account all its characteristics and clinical effects.

Full Text

Restricted Access

About the authors

Dmitry A. Sychev

Russian Medical Academy of Continuous Professional Education

ORCID iD: 0000-0002-4496-3680
SPIN-code: 4525-7556
Scopus Author ID: 7801389135

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Russian Federation, 2/1 Barrikadnaya street, 125993 Moscow

Natalia M. Nenasheva

Russian Medical Academy of Continuous Professional Education

ORCID iD: 0000-0002-3162-2510
SPIN-code: 3363-6170

MD, Dr. Sci. (Med.), Professor

Russian Federation, 2/1 Barrikadnaya street, 125993 Moscow

Oksana V. Sebekina

Russian Medical Academy of Continuous Professional Education; City Clinical Hospital No. 24

ORCID iD: 0000-0002-3508-9602
SPIN-code: 2922-9398
Scopus Author ID: 6503913655

MD, Cand. Sci. (Med.)

Russian Federation, 2/1 Barrikadnaya street, 125993 Moscow; Moscow

Marina Yu. Peredelskaya

Russian Medical Academy of Continuous Professional Education; City Clinical Hospital No. 24

Author for correspondence.
ORCID iD: 0000-0003-2682-8108
SPIN-code: 3363-5507
Scopus Author ID: 57210586164

MD, Cand. Sci. (Med.)

Russian Federation, 2/1 Barrikadnaya street, 125993 Moscow; Moscow


  1. Tiligada E, Ennis M. Histamine pharmacology: From Sir Henry Dale to the 21st century. Br J Pharmacol. 2020;177(3):469–489. doi: 10.1111/bph.14524
  2. Bovet D, Staub AM. Action protective de ethers phenoliques au cours de l’ntoxication histaminique. Compt Rend Soc Biol. 1937;(124):547–549.
  3. Staub AM, Bovet D. Action de la thymoxyethyldiethylamine (925 F) et des ethers phenoliquers sur le choc anaphylactique du cobaye. Com Rend Soc Biol. 1937;(125):818–823.
  4. Orlov EV, Merkulova TB, Konnov PE. Clinical experience of using antihistamine quinuclidine derivatives in combination therapy of itching dermatosis. Klinicheskaya Dermatologiya i Venerologiya. 2014;12(6):74–81. (In Russ).
  5. Goryachkina LA, Peredkova EV. Antihistamines. Textbook. Moscow; 2004. 24 р. (In Russ).
  6. Baroody FM, Naclerio RM. Antiallergic effects of H1-receptor antagonists. Allergy. 2000;55(Suppl 64):17–27. doi: 10.1034/j.1398-9995.2000.00803.x
  7. Reznichenko NY, Reznichenko GI, Kauke YI. Results of a clinical study comparing the efficacy and safety of hifenadine and desloratadine in patients with allergodermatoses. Dermatol Venereol. 2018;1(1):56–66. (In Russ).
  8. Mashkovsky MD, Mutina ES, Kaminka ME. Fencarol and its application in the therapy of allergic diseases. Clin Med. 1978;(11): 22–28. (In Russ).
  9. Moser HR, Giesler GJ. Itch elicited by intradermal injection of serotonin, intracisternal injection of morphine, and their synergistic interactions in rats. Neurosci. 2014;(274):119–127. doi: 10.1016/j.neuroscience.2014.05.025
  10. Dong X, Dong X. Peripheral and central mechanisms of itch. Neuron. 2018;98(3):482–494. doi: 10.1016/j.neuron.2018.03.023
  11. Makarov L, Balykova L, Soldatova O, et al. The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: A randomized controlled pilot trial. Am J Ther. 2010;17(4):396–401. doi: 10.1097/MJT.0b013e3181a86987
  12. Soldatova ON, Balykova LA, Makarov LM, et al. The effectiveness of fencarol in combination with traditional antiarrhythmic agents for extrasystole in children. Bulletin of Peoples’ Friendship University of Russia. 2008;(3):46–51. (In Russ).
  13. Ismailov SR. Effect of phencarol on pancreatic digestive enzymes in food anaphylaxis. Eksp Klin Farmakol. 2001;64(3):48–49.
  14. Bukovskis M, Tirzīte M, Strazda G, et al. H1-antihistamines suppress wheal-and-flare reaction and skin blood perfusion measured by laser doppler flowmetry: Randomized, double-blind, placebo-controlled, crossover design study. Proceedings Latvian Acad Sci. 2010;64(5-6):175–181. doi: 10.2478/v10046-011-0001-9
  15. Luss LV, Tuzlukova EB, Grebenchenko EI. Investigation of antihistamine and sedative effects of Histaphene in patients with allergic rhinoconjunctivitis. Doktor.Ru. 2010;(2):24–29. (In Russ).
  16. Danilycheva IV. Sekhifenadine (histaphene) in the treatment of chronic idiopathic urticaria. Are there any advantages? Russ Allergy J. 2008;(4):66–73. (In Russ).
  17. Luss LV. The use of antihistamines in the clinical practice of a doctor. Therapeutic Archive. 2014;86(8):106–109. (In Russ).
  18. Belan EB, Gutov MV. Antihistamine derivatives of quinuclidines. Clin Dermatol Venereol. 2010;8(5):76–83. (In Russ).
  19. Fedenko EC. Fencarol in the complex therapy of atopic dermatitis and chronic urticaria. Allergy Asthma Clin Immunol. 2003;(6):10–12. (In Russ).
  20. Yashina LA, Feshchenko YI, Ignatieva VA, et al. Fencarol is an effective anti-inflammatory agent in the treatment of persistent allergic rhinitis of mild and moderate severity. Asthma Allergy. 2004;(1-2):41–48. (In Russ).
  21. Clinical study report [Internet]. Quinta No. 741/19 A Phase I, open-label study in healthy male and female subjects under fed condition to assess the pharmacokinetics of Fenkarol 10 mg and 50 mg tablets after single dose oral administration using a randomised, two-arm, parallel-group design and to investigate the multiple-dose pharmacokinetics of Fenkarol 50 mg administered orally after reaching steady stat [2021 Dec 22]. EudraCT number: 2019-004032-40. Data on file.

Supplementary files

Supplementary Files
1. Fig. 1. Overview of the main functions of histamine receptors (adapted from [1]).

Download (792KB)
2. Fig. 2. The level of sedative effect of antihistamines according to the Stanford Sleepiness Scale (adapted from [14]).

Download (641KB)
3. Fig. 3. The average concentration of the drug in different modes of taking the drug. Mode 1 ― a single oral dose of 10 mg of hifenadine (Fencarol); mode 2 ― a single oral dose of hifenadine (Fencarol) at a dose of 50 mg; mode 3 ― oral intake of one tablet of 50 mg with 200 ml of water, provided ingestion twice a day for four days (Taking the drug lasted until the morning of the fifth day, 9 doses in total). Adapted from [21].

Download (639KB)

Copyright © Pharmarus Print Media, 2023

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies